Rezolute, Inc.
RZLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001509261
No open-market purchases or sales by Rezolute, Inc. insiders were filed in the last 90 days; 144 institutions reported holding it in 13F filings for Q2 2026, worth $450.3M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Rezolute, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 35 | 33 | −2 |
| Shares | 24.5M | 24.4M | −91.5K (−0.4%) |
| Value | $79.2M | $67.0M | −$12.2M (−15.4%) |
New holders (3)
Institutions that held Rezolute, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nantahala Capital Management, LLC | 718,736 | $1.97M | 0.19% |
| Tower Research Capital LLC (TRC) | 2,276 | $6.00K | 0.00% |
| Royal Bank of Canada | 67 | $0 | 0.00% |
Sold out (5)
Institutions that held Rezolute, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Altium Capital Management LP | 411,000 | $1.33M |
| Alyeska Investment Group, L.P. | 50,000 | $162.0K |
| Charles Schwab Investment Management Inc | 25,781 | $84.0K |
| Worth Venture Partners, LLC | 12,701 | $38.0K |
| UBS Group AG | 1,741 | $5.00K |